MedTrace Logo

COMT Activity and Hypnotizability

NCT04624880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-04-09

No results posted yet for this study

Summary

Hypnosis is an effective pain management tool for surgery that can reduce opioid use up to 40%. COMT single nucleotide polymorphisms (SNPs) can predict pain sensitivity and opioid use perioperatively, and may also be associated with hypnotizability or response to hypnotic analgesia. Analyzing COMT haplotypes from DNA extracted from saliva or blood using a giant magnetoresistive (GMR) nanotechnology platform may be faster, less expensive, and at least as accurate as pyrosequencing. This study aims to validate a multi-SNP point-of-care (POC) GMR assay for the rapid genotyping of SNPs predictive of COMT activity, and test the feasibility of using COMT activity as a biomarker for hypnotizability and/or response to hypnotic analgesia.

Conditions

  • Pain, Postoperative
  • Genetic Predisposition

Interventions

DEVICE

Giant magnetoresistive sensor (GMR)

Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.

Sponsors & Collaborators

Principal Investigators

  • Shan Wang, PhD · Stanford University

  • David Spiegel, MD · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-13
Primary Completion
2021-07-04
Completion
2021-07-13
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04624880 on ClinicalTrials.gov